SCHEMBL7679546

SCHEMBL7679546

NC(CN1CCc2ccc(Br)cc21)OC(=O)/C=C/C(=O)OC(N)CN1CCc2ccc(Br)cc21

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.64
PMP22 Q01453 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
GFER P55789 1/20 0.64
HTR2A P28223 4/20 0.61
HTR2C P28335 4/20 0.61
HTR2B P41595 4/20 0.61
CYP1A2 P05177 1/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2D6 P10635 1/20 0.61
NFKB1 P19838 1/20 0.61
HIF1A Q16665 1/20 0.61
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
ABHD6 Q9BV23 3/20 0.38
XIAP P98170 2/20 0.36
BIRC2 Q13490 2/20 0.36
CHRM2 P08172 1/20 0.35
CHRM3 P20309 1/20 0.35
MAP3K14 Q99558 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7673512 0.85 HTR2A (0.61) LMNAPMP22NPSR1GFERHTR2A
SCHEMBL7676422 0.81 LMNA (0.43) LMNAPMP22NPSR1GFERHTR2A
SCHEMBL7674586 0.76 HTR2A (1.00) LMNAPMP22NPSR1GFERHTR2A
SCHEMBL29462310 0.76 HTR2A (1.00) LMNAPMP22NPSR1GFERHTR2A
SCHEMBL905755 0.76 HTR2A (1.00) LMNAPMP22NPSR1GFERHTR2A
SCHEMBL7679545 0.74 LMNA (0.65) LMNAPMP22NPSR1GFERHTR2A
SCHEMBL7997579 0.74 LMNA (0.43) LMNAPMP22NPSR1GFERHTR2A
Fumaric Acid SCHEMBL7679552 0.72 LMNA (0.70) LMNAPMP22NPSR1GFERHTR2A
SCHEMBL7832484 0.71 HTR2A (0.55) LMNAPMP22NPSR1GFERHTR2A
SCHEMBL7832870 0.71 LMNA (0.45) LMNAPMP22NPSR1GFERHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6380238-B1 FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA VERNALIS RESEARCH LIMITED (GB) 2002-04-30 US disclosed
EP-1109784-A1 INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2001-06-27 EP disclosed
WO-2000012475-A1 INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2000-03-09 WO disclosed